Lifecore Biomedical to Participate in Craig-Hallum Bioprocessing Conference
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in the upcoming Craig-Hallum Bioprocessing Conference on September 19, 2024. The event will be held virtually, featuring a fireside chat with Lifecore's leadership:
- Paul Josephs, President and CEO
- Ryan Lake, CFO
The fireside chat is scheduled for 3:30 p.m. Eastern on September 19. In addition to the chat, the executives will participate in one-on-one meetings during the conference. A webcast replay of the fireside chat will be made available on Lifecore's investor website following the event.
Positive
- None.
Negative
- None.
CHASKA, Minn., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that Paul Josephs, the Company’s president and chief executive officer, and Ryan Lake, the Company’s chief financial officer, will be the featured speakers in a fireside chat at the upcoming Craig-Hallum Bioprocessing Conference. The conference will take place virtually on September 19, 2024.
Details are as follows:
- Craig-Hallum Bioprocessing Conference
Details: Mr. Josephs and Mr. Lake will participate in a fireside chat and in 1-on-1 meetings
Conference Dates: September 19, 2024
Fireside Chat Timing: 3:30 p.m. Eastern on Thursday, September 19, 2024
Format: Virtual
Following the fireside chat, a webcast replay will be available via a link on Lifecore’s investor website on the Investor Events & Presentations page at: https://ir.lifecore.com/events-presentations.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Lifecore’s website at www.lifecore.com.